MASSNasdaqLaboratory Analytical InstrumentsUS GAAP · USD

908 Devices Inc.

908 Devices Inc. develops handheld chemical analysis instruments designed to deliver rapid, actionable identification of unknown materials at the point of need. The company combines miniaturized mass spectrometry and optical spectroscopy (FTIR) with analytics and machine learning to make field-deployable devices that are smaller and simpler than traditional lab instruments. Its products are used in life-altering health, safety, and defense applications such as fentanyl and illicit drug detection, hazardous material identification, and chemical threat response. The business model is anchored in upfront device placements that create an installed base, followed by recurring revenue from consumables, accessories, software, and service contracts.

Revenue56.2m USD
−5.8 %y/y
Operating profit (EBIT)-39.4m USD
+48.6 %y/y
EBIT margin-70.1%
+58.5 ppy/y
Net income19.5m USD
+127.0 %y/y
Free cash flow-24.6m USD
+20.1 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

-100-50050100m USD2020: 27 m USD2020: EBIT -5.8 m USD20202021: 42 m USD2021: EBIT -22 m USD20212022: 47 m USD2022: EBIT -35 m USD20222023: 50 m USD2023: EBIT -43 m USD20232024: 60 m USD2024: EBIT -77 m USD20242025: 56 m USD2025: EBIT -39 m USD202556-39
RevenueOperating profit (EBIT)

Business

Share of revenue
Device sales (handheld instruments)65 %

Sales of handheld Mass Spec and optical spectroscopy devices (MX908, ThreatID, ProtectIR, XplorIR, VipIR).

Recurring revenue (consumables, accessories, software, services)35 %

Ongoing revenue tied to the installed base, including consumables (e.g., swabs), accessories, software, and service contracts.

Products

Reported · share of revenue
65.2%34.6%FY2025100 %
  • Device Sales65.2 %
  • Recurring34.6 %
  • Contract0.2 %

Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.

Customers

908 Devices sells primarily to government customers and, to a lesser extent, life sciences and industrial customers that need fast chemical identification outside a laboratory. Core end users include law enforcement, military and civilian first responders, and customs and border protection personnel who use handheld devices to detect fentanyl, counterfeit pharmaceuticals, and hazardous bulk materials. The company sells through a mix of direct sales and a broad network of domestic and international channel partners, including situations where a contract vehicle is required. Government procurement cycles can be lengthy and budget-driven, which can concentrate revenue in a small number of large orders and create quarter-to-quarter variability. Each device placement is intended to expand the installed base and pull through recurring consumables and service revenue over time.

U.S. state authorities and local municipalities

Buy handheld devices and recurring consumables/services for frontline drug interdiction and hazardous material identification; purchasing is often tied to municipal/state budgets and grant cycles.

U.S. federal and defense

Procure devices for defense, security, and federal agency field operations where rapid identification of chemical threats and unknowns is mission-critical.

International government (national and provincial)

Purchase primarily through distribution partners for border protection, law enforcement, and emergency response use cases; adoption depends on local safety/security spending and procurement processes.

Pharmaceutical, industrial, and other commercial

Use devices for screening and identification workflows (e.g., counterfeit pharmaceuticals, unknown materials) where portability and speed reduce lab dependence.

Strategy

The company’s strategy centers on growing handheld device placements to expand its installed base and increase pull-through recurring revenue from consumables, accessories, software, and service contracts. It aims to deepen penetration in government end markets while expanding domestically and globally through a combination of direct sales and channel partners, including contract-vehicle-driven routes to market. Product development is guided by customer feedback, with R&D focused on enhancing underlying technology and enabling additional applications through software and chemical libraries. Operationally, the manufacturing model emphasizes in-house assembly and testing for sensitive modules while using contract manufacturers where cost and capital efficiency warrant, alongside ongoing supply-chain diversification. Following the sale of its Desktop Portfolio (reported as discontinued operations), the company is more focused on handheld point-of-need analysis platforms.

Grow device placements to expand the installed baseMedium term

Device sales are a leading indicator of future recurring consumables and services revenue.

Strengthen routes to market via direct sales and channel diversificationShort term

A significant portion of revenue comes through channel partners; concentration increases volatility if partner relationships weaken.

Expand applications and performance through R&D and software-enabled featuresMedium term

New applications increase device utility and can drive additional device and consumables demand.

Geography

Q1/2026

The company sells products worldwide but generates the majority of revenue in the United States, with international sales largely executed through distribution channels. Reported revenue is discussed by end-market customer type rather than a formal regional percentage split, with meaningful contributions from U.S. federal/defense, U.S. state/local authorities, and rest-of-world organizations. Manufacturing is centered in Connecticut, with the primary in-house assembly and test facility in Danbury, supported by precision machining in Stamford, Connecticut and Georgetown, Massachusetts. This U.S.-based manufacturing footprint supports quality control (ISO 9001:2015) and sensitive module assembly in-house, while the supply chain still relies on third-party suppliers for custom components. International expansion increases exposure to shipping lead times, foreign compliance requirements, and potential currency effects (notably the Euro).

United States86 %
Europe, Middle East and Africa9.2 %
Asia Pacific4.7 %

Share of the revenue the company reports by geography.

Risks

Revenue can be volatile because government customers often place large, budget-timed orders after lengthy approval and testing cycles, which can concentrate sales in a small number of customers in a given period. The company also faces channel-partner concentration risk, as partners accounted for a significant portion of revenue and losing motivation or access to key partners could reduce sales. Supply-chain risks include reliance on single-sourced components and consumables (including MX908 sampling swabs) and critical subassemblies, which could disrupt shipments or increase costs if alternatives require validation. International expansion adds risks from foreign regulatory compliance, shipping delays, contract enforcement and collection, and foreign currency movements (notably the Euro). Like other connected device and software-enabled businesses, it is exposed to cybersecurity and data privacy obligations across its own systems and third-party vendors.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Channel partner concentration and relationship risk1Government customer order timing and concentration2Cybersecurity and data privacy compliance failures3Single-sourced consumables (MX908 sampling swabs)4International expansion execution risk5Foreign currency exchange rate fluctuations6
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Channel partner concentration and relationship riskImpact: HighLikelihood: Medium

    Channel partners accounted for a significant portion of revenue; failure to maintain or diversify partners could reduce sales.

    Exposure: Revenue concentration via limited number of large partners

  2. Government customer order timing and concentrationImpact: HighLikelihood: Medium

    Sales cycles are long and budget-driven; large orders can shift between periods and concentrate revenue in few customers.

    Exposure: U.S. federal/defense and state/local procurement

  3. Cybersecurity and data privacy compliance failuresImpact: HighLikelihood: Medium

    Stringent and evolving U.S. and foreign obligations; incidents could lead to investigations, litigation, fines, disruption, and reputational harm.

    ExposureInformation systemsThird-party hosted servicesVendor ecosystem
  4. Single-sourced consumables (MX908 sampling swabs)Impact: MediumLikelihood: Medium

    Swabs are currently single-sourced; replacing requires time to identify/validate alternatives, risking supply continuity.

    Exposure: Recurring revenue tied to MX908 installed base

  5. International expansion execution riskImpact: MediumLikelihood: Low

    Foreign compliance, shipping/acceptance delays, longer payment cycles, and contract enforcement challenges can reduce profitability and cash conversion.

    Exposure: Rest-of-world sales primarily via distribution

  6. Foreign currency exchange rate fluctuationsImpact: MediumLikelihood: Low

    Results may be affected by FX movements, particularly the Euro, if contracts/expenses shift into local currencies over time.

    Exposure: Non-U.S. revenue and supplier costs

Accounting

Judgemental items
Discontinued operations accounting (ASC 205-20) for Desktop Portfolio sale

Disposed business is separated from continuing operations, changing historical comparability and reported income.

Impact: Recast prior periods; gain on sale recognized at closing

Revenue recognition for service and extended warranty contracts

Recognized over the contract term, which can defer revenue relative to cash collection and device placement timing.

Impact: Impacts recurring revenue timing and deferred revenue balances

Valuation of acquired intangibles and goodwill (income approach)

Fair value depends on projected cash flows, growth, renewal probabilities, and discount rates; changes can drive impairment.

Impact: Affects amortization base and potential impairment charges

Publicly listed companies with a comparable business focus.

Last updated: 24/09/2026

908 Devices Inc. (MASS) Revenue, Earnings & Financials 2025 – Clarifo